List of Zyclara drug patents

Zyclara is owned by Bausch.

Zyclara contains Imiquimod.

Zyclara has a total of 9 drug patents out of which 0 drug patents have expired.

Zyclara was authorised for market use on 25 March, 2010.

Zyclara is available in cream;topical dosage forms.

Zyclara can be used as treatment of genital warts; treatment of perianal warts, treatment of actinic keratosis, treatment of perianal warts; treatment of genital warts.

The generics of Zyclara are possible to be released after 30 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Aug, 2029

(6 years from now)

US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Aug, 2029

(6 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream
Dec, 2029

(6 years from now)

US11318130 BAUSCH 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
Dec, 2029

(6 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Dec, 2029

(6 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Apr, 2030

(7 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Apr, 2030

(7 years from now)

Drugs and Companies using IMIQUIMOD ingredient

Market Authorisation Date: 25 March, 2010

Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM;TOPICAL

How can I launch a generic of ZYCLARA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic